Targeting key components of tumor suppressors, such as phosphatase and tensin homolog (PTEN), tuberous sclerosis 1/2 (TSC1/2), neurofibromin 1/2 (NF1/2), or oncogenic mutations in KRAS, PIK3CA, or AKT, may represent an effective treatment to kill acute myeloid leukemia and leukemia stem cells, according to growing evidence (Grabiner et al. 2014). Here, PIK3CA is linked to acute myeloid leukemia.